Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 55Small Cell Lung Carcinoma 39Lung Neoplasms 30Carcinoma, Ovarian Epithelial 29Neuroblastoma 25Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 18Neoplasms 18Leukemia 18Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Sarcoma 10Lymphoma 10Brain Neoplasms 9Recurrence 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasm Metastasis 7Myelodysplastic Syndromes 7Burkitt Lymphoma 7Blast Crisis 7Neuroectodermal Tumors, Primitive, Peripheral 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 6Leukemia, Megakaryoblastic, Acute 6Leukemia, Erythroblastic, Acute 6

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × Topotecan × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡